Guardian Pharmacy Services, Inc.
HealthcareNYSE:GRDN · New York Stock Exchange
+$0.01 today
Vol 0.27M · Avg 0.50M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
23.9%
avg 36.7%
ROIC
22.9%
avg 17.6%
ROA
11.9%
avg 5.3%
Analysis
ROE is currently the strongest return metric at 23.9% versus its period average of 36.7%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Fred Burke | Chief Executive Officer, President & Director | $845,842.00 | — | 76 | $2.14M | 3.38% |
David K. Morris | Chief Financial Officer, Executive Vice President & Director | $756,707.00 | — | 62 | $101,040.00 | 0.16% |
Kendall Forbes | Executive Vice President of Sales & Operations | $754,737.00 | — | 69 | $1.06M | 1.68% |
David Martin | Senior VP of Technology, Data & Senior Security Officer | — | — | — | $101,040.00 | 0.16% |
Will Mudd | SVP of Finance | — | — | — | $98,465.00 | 0.16% |
Bob Weir R.Ph | SVP of Operations & Regulatory Support | — | — | — | $79,883.00 | 0.13% |
Jeff Tuch | SVP of Purchasing & Pricing Analytics | — | — | — | $176,269.00 | 0.28% |
Ashley Stockton | Head of Investor Relations & Senior Director | — | — | — | — | — |
Douglas Towns | SVice President of General Counsel & Senior Compliance Officer | — | — | — | $89,556.00 | 0.14% |
Vicki Crabtree | Vice President of Human Resources | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$99,785.70
Sells
10
$419.26M
Net Sentiment
$419.16M
Net selling
Most Active
Ackerman John
2 transactions
1–10 of 11
Analysis
Insiders reported 1 buys worth $99,785.70 and 10 sells worth $419.26M over the last 12 months. That adds up to net selling of $419.16M. Ackerman John was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +17.2% | +17.2% (6yr)3 analysts |
| Revenue | N/A | N/A | +9.2% | +10.9% (6yr)3 analysts |
| Net Income | N/A | N/A | +17.7% | +15.7% (6yr)3 analysts |
| EBIT | N/A | N/A | +15.1% | -1.2% (6yr)3 analysts |
Analysis
Recent growth has been strongest in Net Income at +17.7% over three years. Forward estimates point to EPS at +17.2% (6yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Twist Bioscience Corporation
NASDAQ:TWST
$4.74B
Edgewise Therapeutics, Inc.
NASDAQ:EWTX
$3.75B
10x Genomics, Inc.
NASDAQ:TXG
$3.66B
National HealthCare Corporation
AMEX:NHC
$3.09B
Pediatrix Medical Group, Inc.
NYSE:MD
$2.00B
Mesoblast Limited
NASDAQ:MESO
$1.79B
Nuvation Bio Inc.
NYSE:NUVB
$1.71B
PROCEPT BioRobotics Corporation
NASDAQ:PRCT
$1.46B
QuidelOrtho Corporation
NASDAQ:QDEL
$963.54M
Janux Therapeutics, Inc.
NASDAQ:JANX
$826.95M
Who manages GRDN?
Guardian Pharmacy Services, Inc. (GRDN) lists 10 active executives. The top listed executive is Kendall Forbes, Executive Vice President of Sales & Operations.
Are GRDN insiders buying or selling?
Recent insider activity shows net selling of $751.61M.
Explore More
Continue the stock analysis
Jump to another research area for this company.